Positive RCT of Rituximab in Systemic sclerosis https://t.co/WsDZeollu0

• https://twitter.com/TheLancetRheum/status/1399748852295557123

Oh, this is a bummer. #EULAR2021 @RheumNow https://t.co/abdEXPU3Bh

Dr Atienza-Mateo presents on IFX ADA TCZ in Behcets refractory uveitic cystoid macular oedema. All appear effective! @RheumNow #EULAR2021 Abstr#OP0060 https://t.co/Vpju0IvrC5

Dr Mekinian presents data showing TCZ and TNFi appear equally effective in TAK, complete response 66% vs 70% at 6 months @RheumNow #EULAR2021 Abstr#OP0068

Dr Kragsnaes presents counter-intuitive data on the gut microbiome. Faecal microbiota transplant ineffective in treating active peripheral psoriatic arthritis, leading to WORSE outcomes. But maybe this also tells us something? @RheumNow #EULAR2021 Abstr#OP0010 https://t.co/nvDvO4Gfxc

Promising preclinical data of novel dual BAFF/APRIL inihibitor ALPN-303 re:efficacy & immunomodulatory activity vs TACI-i. Could deplete plasma cell compared to anti-CD20 mAbs in #SLE. Be interesting to see how it’ll fare in future clinical trials #EULAR2021 #OP0039 @RheumNow https://t.co/LnQzO67gwI

Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr

ProDERM OP0008: IVIG 2g/kg q4w for dermatomyositis vs PBO, open-label extension. TIS score responders 78% vs 43%. IVIG great option: Not immunosuppressive and works fast, watch for headache, pyrexia, nausea, risk of VTE. #EULAR2021 @RheumNow https://t.co/m4CEkg3EyC

We know smoking is ass w/ RA. How about passive 🚬? French E3N-EPIC cohort: OP0012. Prospective questionaries of 80,000F, 698 incident cases. ⬆️ risk in passive childhood and adult tobacco exposure. #EULAR2021 @RheumNow 🚭! https://t.co/1Rf0euz3VC

OP0010 at #EULAR2021. FLORA trial: Fecal microbiota transplant as add-on Rx to MTX. Small trial showing time-to-event curves show inferiority to sham but good safety. Fascinating concept exploring gut-joint interaction. @RheumNow. https://t.co/BIOmA5z6vK

Some interesting abstracts at #EULAR2021 today on monitoring GCA with: - ultrasound OP0055 https://t.co/0fqLIK5IPV - PET/CT OP0069 https://t.co/WQl9VaHR9E OP0064 https://t.co/w7biFT6qy0 What do you believe is the most accurate measure of true disease activity in GCA? @RheumNow

• https://ard.bmj.com/content/80/Suppl_1/29
• https://ard.bmj.com/content/80/Suppl_1/37.2
• https://ard.bmj.com/content/80/Suppl_1/34.2

Dr Arnold @Yuz6Yusof present on personalised rituximab retreatment in AAV. Interesting that naive B-cell repopulation at 6 months predicts better sustained response compared to absence @RheumNow #EULAR2021 Abstr#OP0057 https://t.co/cypyQVMeYz

IVIG pending FDA review for tx of dermatomyositis after ProDERM study. Do you use IVIG for tx of DM? #EULAR2021 @RheumNow

ProDERM RCT IVIG in Dermatomyositis ⭐️improved TIS scores compared to pbo ⭐️common AE: headaches, pyrexia, nausea ⭐️serious AE: PE, CVA, DVT ⭐️approved in Europe, pending FDA Abs#OP0008 #EULAR2021 @RheumNow

Comparison of disease activity and PROs in AxSpA vs. AxPsA ⭐️AxSpA ⬆️ uveitis and IBD ⭐️AxPsA ⬆️enthesitis and dactylitis ⭐️AxSpA pts ⬆️pain, spinal pain PROs ⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb